GPR89A | G protein-coupled receptor 89A | Predicted membrane proteins
| | | | | Expressed in all |
GPR89C | G protein-coupled receptor 89C | Predicted membrane proteins
| | | | | Expressed in all |
GRINA | Glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding) | Predicted membrane proteins
| | | | | Expressed in all |
HCN1 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 1 | Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
HCN3 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 3 | Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
HCN4 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 4 | Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
HHATL | Hedgehog acyltransferase-like | Predicted membrane proteins
| | | | | Group enriched |
HRH4 | Histamine receptor H4 | G-protein coupled receptors Predicted membrane proteins
| | | | | Not detected |
HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNA6 | Potassium voltage-gated channel, shaker-related subfamily, member 6 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNA7 | Potassium voltage-gated channel, shaker-related subfamily, member 7 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNF1 | Potassium voltage-gated channel, subfamily F, member 1 | Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNH1 | Potassium voltage-gated channel, subfamily H (eag-related), member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNH2 | Potassium voltage-gated channel, subfamily H (eag-related), member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH3 | Potassium voltage-gated channel, subfamily H (eag-related), member 3 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH6 | Potassium voltage-gated channel, subfamily H (eag-related), member 6 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK15 | Potassium channel, subfamily K, member 15 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK16 | Potassium channel, subfamily K, member 16 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNK17 | Potassium channel, subfamily K, member 17 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNK3 | Potassium channel, subfamily K, member 3 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK4 | Potassium channel, subfamily K, member 4 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK6 | Potassium channel, subfamily K, member 6 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNK7 | Potassium channel, subfamily K, member 7 | Predicted membrane proteins Predicted secreted proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNK9 | Potassium channel, subfamily K, member 9 | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Group enriched |
KCNN1 | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNN3 | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ2 | Potassium voltage-gated channel, KQT-like subfamily, member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNQ3 | Potassium voltage-gated channel, KQT-like subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNQ4 | Potassium voltage-gated channel, KQT-like subfamily, member 4 | Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNQ5 | Potassium voltage-gated channel, KQT-like subfamily, member 5 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNS1 | Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 1 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNV1 | Potassium channel, subfamily V, member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNV2 | Potassium channel, subfamily V, member 2 | Disease related genes Potential drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KDELR2 | KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 | Predicted membrane proteins
| | | | | Expressed in all |
KIAA0195 | KIAA0195 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
LAPTM5 | Lysosomal protein transmembrane 5 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
LHFPL3 | Lipoma HMGIC fusion partner-like 3 | Predicted membrane proteins
| | | | | Tissue enriched |
LMF1 | Lipase maturation factor 1 | Disease related genes Predicted membrane proteins
| | | | | Expressed in all |
LPPR3 | Hsa-mir-3187 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
MBOAT7 | Membrane bound O-acyltransferase domain containing 7 | Enzymes Predicted membrane proteins
| | | | | Expressed in all |
MBTPS2 | Membrane-bound transcription factor peptidase, site 2 | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Expressed in all |
MCOLN2 | Mucolipin 2 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
MCOLN3 | Mucolipin 3 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
MFSD11 | Major facilitator superfamily domain containing 11 | Predicted membrane proteins
| | | | | Expressed in all |
MFSD12 | Major facilitator superfamily domain containing 12 | Predicted membrane proteins
| | | | | Expressed in all |
MFSD6 | Major facilitator superfamily domain containing 6 | Predicted membrane proteins
| | | | | Expressed in all |
MLC1 | Megalencephalic leukoencephalopathy with subcortical cysts 1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
MLNR | Motilin receptor | G-protein coupled receptors Predicted membrane proteins
| | | | | Not detected |